NCT06650579 - REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2029

Conditions

Recurrent Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

Interventions

DRUG

Abiraterone Acetate

Given abiraterone acetate

DRUG

Bicalutamide

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography Angiography

Undergo CCTA

DRUG

Leuprolide

Given IM or SC

DRUG

Prednisone

Given prednisone

RADIATION

Radiation Therapy

Undergo standard of care radiation therapy

DRUG

Relugolix

Given PO

Trial Locations (4)

RECRUITING

Emory Proton Therapy Center, Atlanta

RECRUITING

Winship at Emory Midtown, Atlanta

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

RECRUITING

Emory Saint Joseph's Hospital, Atlanta